65 related articles for article (PubMed ID: 2074385)
21. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
[TBL] [Abstract][Full Text] [Related]
22. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
23. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
26. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
27. [Biochemical modulation of 5-FU--effect of low dose CDDP].
Hirata K; Yamamitsu S; Tsuji A; Shirasaka T; Mukaiya M; Oikawa I; Kimura H; Sasaki K; Denno R
Gan To Kagaku Ryoho; 1999 Mar; 26(4):467-75. PubMed ID: 10097743
[TBL] [Abstract][Full Text] [Related]
28. [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
Meguro E; Kimura T; Noda Y; Matsumoto Y; Irinoda T; Hayakawa Y; Kobayashi M; Takagane A; Hioki J
Gan To Kagaku Ryoho; 2007 Feb; 34(2):249-52. PubMed ID: 17301537
[TBL] [Abstract][Full Text] [Related]
29. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
31. [The histological antitumor effect and side effects of preoperative chemotherapy for patients with oral squamous cell carcinoma--comparison between low-dose and high-dose CDDP regimens].
Nakazawa M; Iwai S; Moriyama T; Kato I; Uekusa Y; Katagiri W; Takeuchi N; Matsumoto K; Sakuda M
Gan To Kagaku Ryoho; 2001 Mar; 28(3):337-43. PubMed ID: 11265401
[TBL] [Abstract][Full Text] [Related]
32. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer].
Yabusaki H; Nashimoto A; Tanaka O
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1933-40. PubMed ID: 14650962
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
35. [Local injection of high-dose CDDP to the advanced gynecological cancer].
Hashii K; Takahashi A; Kanto T; Ukita M; Tateyama I; Natsuyama S; Mori T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1472-81. PubMed ID: 2212837
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
Fanning J; Colgrove M; Phibbs G
Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
38. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of the efficacy of cisplatin-based chemotherapy in epithelial ovarian cancer; comparison with treatments employed before the cisplatin era].
Kamura T; Tsukamoto N; Suenaga T; Kaku T; Matsukuma K; Matsuyama T
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1260-3. PubMed ID: 3579324
[TBL] [Abstract][Full Text] [Related]
40. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
